Literature DB >> 20353984

Antiprothrombin antibody: why do we need more assays?

T Atsumi1, T Koike.   

Abstract

Anticardiolipin antibodies (aCL), anti-beta(2)-glycoprotein I (beta(2)GPI) antibodies and lupus anticoagulant (LA) are the only laboratory tests considered within the revised criteria for the classification of the antiphospholipid syndrome (APS). Recently, the significance to assay the antibodies against phosphatidylserine-prothrombin complex (aPS/PT) has been discussed, and these antibodies, rather than antibodies against prothrombin alone, are closely associated with APS and LA. The sensitivity and specificity of aPS/PT for the diagnosis of APS were assessed in a population of patients with a variety of autoimmune disorders. The aCL and aPS/PT have similar diagnostic value for APS, and most of APS patients with aPS/PT had positive LA. Therefore, aPS/PT should be further explored, not only for research purposes, but also as a candidate for one of the enzyme-linked immunosorbent assay (ELISA)-based confirmatory test for APS associated LA.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20353984     DOI: 10.1177/0961203310361487

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  11 in total

Review 1.  Clinical Risk Assessment in the Antiphospholipid Syndrome: Current Landscape and Emerging Biomarkers.

Authors:  Shruti Chaturvedi; Keith R McCrae
Journal:  Curr Rheumatol Rep       Date:  2017-07       Impact factor: 4.592

2.  APhL antibody ELISA as an alternative to anticardiolipin test for the diagnosis of antiphospholipid syndrome.

Authors:  Brenda B Suh-Lailam; Anndorie Cromar; K Wayne Davis; Anne E Tebo
Journal:  Int J Clin Exp Pathol       Date:  2012-03-25

3.  Comparative analysis of different enzyme immunoassays for assessment of phosphatidylserine-dependent antiprothrombin antibodies.

Authors:  Olga Amengual; Tetsuya Horita; Walter Binder; Gary L Norman; Zakera Shums; Masaru Kato; Kotaro Otomo; Yuichiro Fujieda; Kenji Oku; Toshiyuki Bohgaki; Shinsuke Yasuda; Tatsuya Atsumi
Journal:  Rheumatol Int       Date:  2014-02-05       Impact factor: 2.631

4.  Thrombotic microangiopathy due to multiple autoantibodies related to antiphospholipid syndrome.

Authors:  Shunsuke Noda; Masao Ogura; Akiko Tsutsumi; Tomohiro Udagawa; Koichi Kamei; Kentaro Matsuoka; Hiroshi Kitamura; Tatsuya Atsumi; Shuichi Ito
Journal:  Pediatr Nephrol       Date:  2011-12-31       Impact factor: 3.714

5.  Diagnostic value of antibodies to phosphatidylserine/prothrombin complex for antiphospholipid syndrome in Chinese patients.

Authors:  Lei Zhu; Chun Li; Na Liu; Xin Yang; R L Jia; Rong Mu; Yin Su; Z G Li
Journal:  Clin Rheumatol       Date:  2017-01-03       Impact factor: 2.980

6.  Anti-phosphatidylserine/prothrombin antibodies: an additional diagnostic marker for APS?

Authors:  Francesca Pregnolato; Cecilia B Chighizola; Susan Encabo; Zakera Shums; Gary L Norman; Armando Tripodi; Veena Chantarangkul; Tiziana Bertero; Valeria De Micheli; Maria Orietta Borghi; Pier Luigi Meroni
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

7.  Bouquet variety of antiphospholipid antibodies in recurrent pregnancy loss.

Authors:  Marta P Baleva; Zhivka P Karagyozova; Milena K Nikolova-Vlahova; Krasimir V Nikolov; Petar K Nikolov
Journal:  Cent Eur J Immunol       Date:  2014-10-14       Impact factor: 2.085

8.  Phosphatidylserine-dependent anti-prothrombin antibodies (aPS/PT) in infliximab-treated patients with inflammatory bowel diseases.

Authors:  Karin Malíčková; Dana Ďuricová; Martin Bortlík; Ivana Janatková; Tomáš Zima; Milan Lukáš
Journal:  Auto Immun Highlights       Date:  2012-12-23

9.  Detection of antiphosphatidylserine/prothrombin antibodies and their potential diagnostic value.

Authors:  Polona Žigon; Saša Čučnik; Aleš Ambrožič; Tanja Kveder; Snežna Sodin Šemrl; Blaž Rozman; Borut Božič
Journal:  Clin Dev Immunol       Date:  2013-09-26

Review 10.  Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers.

Authors:  Pier Luigi Meroni; Cecilia Beatrice Chighizola; Francesca Rovelli; Maria Gerosa
Journal:  Arthritis Res Ther       Date:  2014       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.